Perjeta (pertuzumab)

Numéro de dossier de l’APP: 21742
État des négociations:
Under consideration for negotiation
Indication(s):
In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either 2 cm in diameter or node positive)
Promoteur/fabricant:
HOFFMANN-LA ROCHE LIMITED 
Numéro de projet de l’ACMTS:
PC0241
Lettre-contrat de l’APP:
Not Applicable
Conclusion du processus de négociation:
Not Applicable